These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 772555)

  • 21. Induced immunotolerance in factor VIII inhibitor patients.
    Brackmann HH
    Prog Clin Biol Res; 1984; 150():181-95. PubMed ID: 6431426
    [No Abstract]   [Full Text] [Related]  

  • 22. Novel therapies for immune tolerance in haemophilia A.
    Collins PW
    Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Long-term remission after i.v. immunoglobulin therapy in acquired antihemophilic factor hemophilia with systemic lupus erythematosus].
    Pirner K; Rösler W; Kalden JR; Manger B
    Z Rheumatol; 1990; 49(6):378-81. PubMed ID: 2128157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solid tumors and factor VIII antibodies.
    Hauser I; Lechner K
    Thromb Haemost; 1999 Sep; 82(3):1005-7. PubMed ID: 10494753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired factor VIII inhibitor associated with prostatic cancer: successful treatment with steroid and immunosuppressive therapy.
    Moccia F; Tognoni E; Boccaccio P
    Ann Ital Med Int; 2000; 15(2):172-6. PubMed ID: 10920509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired haemophilia: functional study of antibodies to Factor VIII.
    Allain JP; Gaillandre A; Frommel D
    Thromb Haemost; 1981 Jun; 45(3):285-9. PubMed ID: 6792741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of inhibitors to factor VIII and IX.
    Roberts HR; Cromartie R
    Prog Clin Biol Res; 1984; 150():1-18. PubMed ID: 6431420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ; Fenske TS; Blinder MA
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten-year longitudinal study.
    Tinlin S; Webster S; Giles AR
    Thromb Haemost; 1993 Jan; 69(1):21-4. PubMed ID: 8446933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies.
    Green D; Rademaker AW; Briët E
    Thromb Haemost; 1993 Nov; 70(5):753-7. PubMed ID: 8128430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.
    Hay CR; Ludlam CA; Colvin BT; Hill FG; Preston FE; Wasseem N; Bagnall R; Peake IR; Berntorp E; Mauser Bunschoten EP; Fijnvandraat K; Kasper CK; White G; Santagostino E
    Thromb Haemost; 1998 Apr; 79(4):762-6. PubMed ID: 9569189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 33. Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A?
    Lindgren A; Wadenvik H; Tarkowski A; Tengborn L
    Thromb Haemost; 2000 Apr; 83(4):632-3. PubMed ID: 10780332
    [No Abstract]   [Full Text] [Related]  

  • 34. Haemophilia A: mutation type determines risk of inhibitor formation.
    Schwaab R; Brackmann HH; Meyer C; Seehafer J; Kirchgesser M; Haack A; Olek K; Tuddenham EG; Oldenburg J
    Thromb Haemost; 1995 Dec; 74(6):1402-6. PubMed ID: 8772209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Failure of combined factor VIII and cyclophosphamide to suppress antibody to factor VIII in hemophilia.
    Hruby MA; Schulman I
    Blood; 1973 Dec; 42(6):919-23. PubMed ID: 4759918
    [No Abstract]   [Full Text] [Related]  

  • 36. Factor VIII Inhibitors. Natural autoantibodies and anti-idiotypes.
    Gilles JG; Vanzieleghem B; Saint-Remy JM
    Semin Thromb Hemost; 2000; 26(2):151-5. PubMed ID: 10919407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combined treatment with factor VIII and immunosuppressive agents in a young woman with acquired factor VIII inhibitor].
    José Aguado M; Carrasco V; Periago A; Bello T; González E; García-Talavera J
    Sangre (Barc); 1996 Apr; 41(2):147-50. PubMed ID: 9045356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated ppsb in the treatment of a patient with haemophilia and antibodies to factor VIII.
    Ekert H; McVeagh P
    Med J Aust; 1975 Oct; 2(17):675-7. PubMed ID: 1207551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of two patients with acquired factor VIII inhibitors using cyclophosphamide and prednisone.
    Hertzberg MS; Favaloro E; Koutts J
    Am J Hematol; 2002 Aug; 70(4):330-1. PubMed ID: 12210817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.